Compare ASX & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASX | VRTX |
|---|---|---|
| Founded | 1984 | 1989 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | EDP Services |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.0B | 123.4B |
| IPO Year | 2000 | 2006 |
| Metric | ASX | VRTX |
|---|---|---|
| Price | $36.51 | $548.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 29 |
| Target Price | N/A | ★ $539.69 |
| AVG Volume (30 Days) | ★ 8.3M | 1.3M |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | N/A | ★ 836.54 |
| EPS | N/A | ★ 8.33 |
| Revenue | N/A | ★ $2,488,652,000.00 |
| Revenue This Year | $19.16 | $10.79 |
| Revenue Next Year | $16.13 | $10.47 |
| P/E Ratio | ★ $38.05 | $64.85 |
| Revenue Growth | N/A | ★ 46.20 |
| 52 Week Low | $9.86 | $374.17 |
| 52 Week High | $45.52 | $553.69 |
| Indicator | ASX | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.88 | 66.65 |
| Support Level | $30.50 | $458.05 |
| Resistance Level | $40.70 | N/A |
| Average True Range (ATR) | 1.48 | 15.20 |
| MACD | -0.10 | 4.34 |
| Stochastic Oscillator | 22.31 | 89.92 |
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, Electronic Manufacturing Services and others. Of these, Packaging segment contribute the maximum revenue. The packaging segment involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufactures, and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but generates over half its sales from firms in the United States.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.